
Long-Lasting Inhibition of Radiographic Progression Shown with Secukinumab for Psoriatic Arthritis
Treatment with secukinumab (Cosentyx, Novartis) inhibited radiographic progression in most patients with psoriatic arthritis over 2 years in a phase 3 trial.
























